

2012

CcpA Regulates Arginine Biosynthesis in *Staphylococcus aureus* through Repression of Proline Catabolism

Austin S. Nuxoll

University of Nebraska Medical Center

Steven M. Halouska

University of Nebraska-Lincoln

Marat R. Sadykov

University of Nebraska Medical Center

Mark L. Hanke

University of Nebraska Medical Center

Kenneth W. Bayles

University of Nebraska Medical Center, kbayles@unmc.edu

See next page for additional authors

Follow this and additional works at: <http://digitalcommons.unl.edu/chemfacpub>

 Part of the [Analytical Chemistry Commons](#), [Medicinal-Pharmaceutical Chemistry Commons](#), and the [Other Chemistry Commons](#)

Nuxoll, Austin S.; Halouska, Steven M.; Sadykov, Marat R.; Hanke, Mark L.; Bayles, Kenneth W.; Kielian, Tammy; Powers, Robert; and Fey, Paul D., "CcpA Regulates Arginine Biosynthesis in *Staphylococcus aureus* through Repression of Proline Catabolism" (2012). *Faculty Publications -- Chemistry Department*. 77.
<http://digitalcommons.unl.edu/chemfacpub/77>

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications -- Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors

Austin S. Nuxoll, Steven M. Halouska, Marat R. Sadykov, Mark L. Hanke, Kenneth W. Bayles, Tammy Kielian, Robert Powers, and Paul D. Fey

CcpA Regulates Arginine Biosynthesis in *Staphylococcus aureus* through Repression of Proline Catabolism

Austin S. Nuxoll¹, Steven M. Halouska², Marat R. Sadykov¹, Mark L. Hanke¹, Kenneth W. Bayles¹, Tammy Kielian¹, Robert Powers², Paul D. Fey^{1*}

¹ Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America, ² Department of Chemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America

Abstract

Staphylococcus aureus is a leading cause of community-associated and nosocomial infections. Imperative to the success of *S. aureus* is the ability to adapt and utilize nutrients that are readily available. Genomic sequencing suggests that *S. aureus* has the genes required for synthesis of all twenty amino acids. However, *in vitro* experimentation demonstrates that staphylococci have multiple amino acid auxotrophies, including arginine. Although *S. aureus* possesses the highly conserved anabolic pathway that synthesizes arginine via glutamate, we demonstrate here that inactivation of *ccpA* facilitates the synthesis of arginine via the urea cycle utilizing proline as a substrate. Mutations within *putA*, *rocD*, *arcB1*, *argG* and *argH* abolished the ability of *S. aureus* JE2 *ccpA::tetL* to grow in the absence of arginine, whereas an interruption in *argJBCF*, *arcB2*, or *proC* had no effect. Furthermore, nuclear magnetic resonance demonstrated that JE2 *ccpA::ermB* produced ¹³C₅ labeled arginine when grown with ¹³C₅ proline. Taken together, these data support the conclusion that *S. aureus* synthesizes arginine from proline during growth on secondary carbon sources. Furthermore, although highly conserved in all sequenced *S. aureus* genomes, the arginine anabolic pathway (ArgJBCDFGH) is not functional under *in vitro* growth conditions. Finally, a mutation in *argH* attenuated virulence in a mouse kidney abscess model in comparison to wild type JE2 demonstrating the importance of arginine biosynthesis *in vivo* via the urea cycle. However, mutations in *argB*, *argF*, and *putA* did not attenuate virulence suggesting both the glutamate and proline pathways are active and they, or their pathway intermediates, can complement each other *in vivo*.

Citation: Nuxoll AS, Halouska SM, Sadykov MR, Hanke ML, Bayles KW, et al. (2012) CcpA Regulates Arginine Biosynthesis in *Staphylococcus aureus* through Repression of Proline Catabolism. PLoS Pathog 8(11): e1003033. doi:10.1371/journal.ppat.1003033

Editor: Michael S. Gilmore, Harvard Medical School, United States of America

Received: March 21, 2012; **Accepted:** October 1, 2012; **Published:** November 29, 2012

Copyright: © 2012 Nuxoll et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The Protein Structure Core Facility, University of Nebraska Medical Center, is supported by the Nebraska Research Initiative. This work is supported in part by funds from NIH/NIAID P01A1083211 to P.D.F., K.W.B., and T.K. and the NIH National Center for Research Resources to R.P. (P20 RR-17675). NMR analyses were performed in facilities renovated with support from NIH (RR015468-01) provided funding for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: pfey@unmc.edu

Introduction

Staphylococcus aureus is a common cause of skin and soft tissue infections; however more serious complications such as bacteremia, osteomyelitis, endocarditis, and necrotizing pneumonia can occur [1]. During infection, *S. aureus* must catabolize diverse carbon sources including carbohydrates, proteins and lipids; therefore, multiple global regulators, including CcpA and CodY, subsequently regulate carbon flow [2,3,4]. Thus, regulation of carbon flow through central metabolism and other metabolic pathways has a direct link to expression and synthesis of virulence factors [5,6,7].

It has been known for over 70 years that *S. aureus* exhibits multiple amino acid auxotrophies, including arginine, valine, proline, cysteine, and leucine [8,9]. Complicating the picture, in 1937, Gladstone demonstrated that multiple strains of *S. aureus* could be trained to grow in a chemically-defined broth lacking all twenty amino acids through extended incubation [9]. These data suggested that *S. aureus* was indeed a prototroph but repressed biosynthesis of certain amino acids. In support of this, bioinformatic analyses of the *S. aureus* genome revealed an apparently complete repertoire of biosynthetic operons needed to synthesize

all 20 amino acids [10]. Included in these are the genes encoding the arginine biosynthetic pathway *argJBCDFGH* where arginine is synthesized from glutamate [11]. This pathway is highly conserved among a wide array of bacteria, including *Escherichia coli*, *Salmonella enterica* serotype Typhimurium, *Proteus mirabilis*, *Bacillus subtilis*, and *Streptomyces clavuligerus* among others [12,13,14].

Although *B. subtilis* synthesizes proline from glutamate [11,15,16], *S. aureus* preferentially utilizes arginine rather than glutamate as a precursor for proline biosynthesis via arginase (RocF), ornithine aminotransferase (RocD), and P5C reductase (ProC) [17]. Furthermore, Li and colleagues recently reported that proline biosynthesis is regulated through CcpA-mediated carbon catabolite repression at both *rocF* and *rocD* [18]. Carbon catabolite repression allows bacteria to preferentially utilize preferred carbon sources and therefore increase the organism's fitness [19]. The *trans*-acting carbon catabolite protein CcpA in a complex with Hpr binds to *cis*-acting DNA sequences known as catabolite responsive elements (CRE) [20,21,22,23]. In the presence of a preferred carbon source, HprK phosphorylates the Ser-46 position of Hpr and once phosphorylated, Hpr binds to CcpA [23,24,25].

In this study, we utilized genetic and biochemical approaches to examine arginine auxotrophy in *S. aureus*. *bursa aurealis* transposon

Author Summary

Although *Staphylococcus aureus* encodes the highly conserved arginine biosynthesis pathway via glutamate, arginine is an essential amino acid. We found that a mutation in *ccpA*, a gene encoding a protein facilitating carbon catabolite repression, mediates arginine biosynthesis under *in vitro* growth conditions. However, both genetic and biochemical evidence suggested that a *S. aureus* *ccpA* mutant synthesizes arginine via proline and the urea cycle, a pathway not demonstrated in bacteria before. Furthermore, an animal model of *S. aureus* infection demonstrated the importance of arginine biosynthesis *in vivo*. This new pathway sheds light on important host-pathogen interactions and suggests *S. aureus* has evolved to address arginine depletion in the host by synthesizing arginine from a readily available substrate such as proline.

mutagenesis identified CcpA as a regulator of arginine biosynthesis. However, instead of de-repressing the conserved arginine biosynthesis pathway (ArgJBCDFGH) via glutamate, *S. aureus* JE2 *ccpA* synthesized arginine from proline via the urea cycle. To the best of our knowledge, this is the first report of bacteria utilizing proline for arginine biosynthesis, which may indicate a predilection to degrade and utilize proteins rich in proline (i.e. collagen) during an *S. aureus* infection for use in arginine biosynthesis. Utilization of proline to synthesize arginine demonstrates the resourcefulness of *S. aureus* and its ability to rapidly evolve to utilize nutrients that are readily available in the environment.

Results

Arginine Auxotrophy in *Staphylococcus aureus*

To examine arginine auxotrophy in *S. aureus*, eighty-two clinical *S. aureus* isolates collected from positive blood cultures at the University of Nebraska Medical Center were grown on Complete Defined Medium (CDM) with and without arginine. Similar to observations by Emmett and Kloos, only one *S. aureus* isolate (SA2126) had the ability to grow on CDM lacking arginine (CDM-R) following 48 h incubation, whereas all isolates grew on CDM containing arginine further confirming the arginine auxotrophic nature of *S. aureus* [8]. Furthermore, a community-associated *S. aureus* USA300 strain JE2 (Table S1) was unable to grow on CDM-R following 48 h incubation at 37°C. To extend these observations, JE2 was grown to stationary phase in CDM broth (5×10^9 CFU) and plated on CDM-R and CDM lacking proline (CDM-P). Similar to the observations of Li and colleagues [18], *S. aureus* JE2 reverted to proline prototrophy at a rate of 1×10^{-6} ; however, no colonies were isolated on CDM-R following five experimental attempts. Nevertheless, similar to observations by Gladstone, slight growth of JE2 was observed following five days of incubation in CDM-R broth [9]. These observations suggest that *S. aureus* has the inherent ability to synthesize arginine upon extended selection; however, the phenotype is not easily selected during growth in medium replete with amino acids.

Regulation of Arginine Biosynthesis by Carbon Catabolite Repression

Based on our observations that growth in CDM-R could be selected through extended incubation, we hypothesized that arginine biosynthesis was under transcriptional repression. Therefore, we screened a random *bursa aurealis* transposon library to isolate JE2 mutants able to grow on CDM-R. Two mutants were

isolated that had the ability to grow on CDM-R; subsequent sequencing of the *bursa aurealis* insertions found they had inserted in *hprK* and *ccpA*. Both HprK and CcpA function to control carbon catabolite repression (CCR) in gram-positive bacteria [26]. Therefore, to completely eliminate CCR, a *ccpA* allelic replacement mutant was generated in JE2 through 80% transduction of the *ccpA::tetL* allele from MST14 (kind gift of M. Bischoff). As predicted, growth analysis in CDM-R demonstrated that JE2 *ccpA::tetL* enters exponential phase between 7–12 h and reaches a maximum OD₆₀₀ of 4.5 after 24 h, whereas no growth was observed with wild type JE2 in CDM-R (Figure 1). Importantly, introduction of the *ccpA* complementation plasmid pNF266 abrogated growth of JE2 *ccpA::tetL*.

To further support the hypothesis that CCR functions to repress arginine biosynthesis, JE2 was grown in CDM-R lacking glucose but containing other, non-preferred carbon sources (Figure 2). Since CCR is alleviated when *S. aureus* is grown in media containing a non-preferred carbon source, it was hypothesized that JE2 would grow in CDM-R when glucose was replaced with a secondary carbon source. These experiments demonstrated that arabinose, sorbitol and pyruvate were able to support growth of JE2 when added to CDM-R (Figure 2). In contrast, glucose, fructose, glycerol, sucrose, mannitol, maltose, salicin, gluconic acid, and ribose were unable to support growth in CDM-R suggesting these carbohydrates do not derepress CcpA in JE2. In agreement with our results, Li and colleagues also determined that replacement of glucose with arabinose or sorbitol abrogated CcpA-mediated repression in *S. aureus* Newman and functioned to activate proline biosynthesis [18]. Overall, these data demonstrate that CCR functions to repress arginine biosynthesis, suggesting that arginine biosynthesis is linked to growth in niches where preferred carbon sources are limited.

Northern Analysis of *argJBCDFGH* in JE2 *ccpA::ermB*

Our preliminary data suggested that CCR functioned to repress an enzymatic step in the conserved arginine biosynthetic pathway via glutamate [27] (Figure 3). To further address this possibility, northern blot analysis was performed to address transcriptional expression of *argJBCDFGH* in JE2 *ccpA::ermB* in comparison to




Figure 1. Interruption of *ccpA* facilitates growth in CDM-R. Growth analysis of JE2, JE2 *ccpA::tetL*, and JE2 *ccpA::tetL*/pNF266 (*ccpA* complement) in complete defined medium lacking arginine (CDM-R). Isolates were grown aerobically using a 10:1 flask to volume ratio. *S. aureus* strains containing a functional *ccpA* are unable to grow in CDM-R. Data represent means \pm SEM of three independent experiments. doi:10.1371/journal.ppat.1003033.g001




Figure 2. Growth of JE2 in CDM containing non-preferred carbon sources. JE2 was grown in CDM or CDM-R with the indicated carbon source at 37°C for 18 hours. Significant growth in CDM-R was seen only when arabinose and sorbitol were used as carbon sources. Data represent means \pm SEM of five independent experiments. doi:10.1371/journal.ppat.1003033.g002

wildtype JE2. In *S. aureus*, *argDC7B* is arranged in an operon structure, whereas *argF* is transcribed as a monocistronic unit and *argGH* are co-transcribed. JE2 and JE2 *ccpA::ermB* were grown in CDM and CDM-R, respectively, to mid-exponential phase and




Figure 4. Northern analysis of arginine biosynthetic pathway in *S. aureus* JE2 and JE2 *ccpA::ermB*. JE2 and JE2 *ccpA::ermB* total RNA was isolated in mid-exponential phase of growth in CDM and CDM-R, respectively. DNA probes specific for *argJ*, *argB*, *argC*, *argD*, *argF*, *argG*, and *argH* were labeled with digoxigenin and detected using anti-digoxigenin-AP Fab fragments (Panel A). Panel B shows 16 s and 23 s rRNA depicting equal RNA loading. doi:10.1371/journal.ppat.1003033.g004

mRNA was isolated. Utilizing DNA probes specific for each gene within the conserved pathway, *argDC7B* and *argF* expression was not detected in either JE2 or JE2 *ccpA::ermB* (Figure 4). However, although *argG* and *argH* transcripts were not detected in JE2, both transcripts were detected in JE2 *ccpA::ermB* (Figure 4). Therefore, although JE2 *ccpA::ermB* has the ability to grow on media lacking arginine, this strain does not appear to utilize the conserved arginine biosynthetic operon to synthesize arginine in CDM-R. These results suggested the existence of a novel arginine biosynthetic pathway in *S. aureus*.

S. aureus Utilizes a Novel Proline Catabolic Pathway to Synthesize Arginine

Since our data indicated that glutamate was not the precursor for arginine synthesis in JE2 *ccpA::ermB*, other potential pathways were examined *in silico*. Based on the northern blot data demonstrating the expression of *argGH* in JE2 *ccpA::ermB*, we hypothesized that arginine may be synthesized via the urea cycle (Figure 3). *In silico* analysis predicted that either glutamate or proline have the potential to feed into the urea cycle to serve as substrates for arginine biosynthesis. To address this hypothesis, we examined amino acid consumption by JE2 and JE2 *ccpA::ermB* grown in CDM and CDM-R, respectively (Figure S1). These results demonstrated that both JE2 and JE2 *ccpA::ermB* consumed similar amounts of glutamate from the culture media following 24 h of growth. In contrast, JE2 *ccpA::ermB* consumed all available free proline from the culture medium, whereas only approximately 50% of the available free proline was consumed by JE2. Taken together, these observations allowed us to speculate that JE2 *ccpA::ermB* utilized proline via the urea cycle for arginine synthesis.

To further investigate this hypothesis, $\phi 11$ transducing lysates were prepared from defined JE2 *bursa aurealis* mutants with insertions in the following genes: *putA*, *proC*, *rocD*, *arcB1*, *arcB2*, *argF*, *argG*, *argH*, *argC*, *argB* and *argJ*. These *bursa aurealis* mutations (conferring erythromycin resistance) were transduced into JE2 *ccpA::tetL* and subsequently grown in CDM-R (Figure 5). Mutations in *argG*, *argH*, *putA*, *rocD*, and *arcB1* abrogated growth of JE2 *ccpA::tetL* in CDM-R. However, mutations in *argJ*, *argB*, *argC*, *argF*, *arcB2*, or *proC* had no effect on growth consistent with the prediction that arginine is synthesized from proline and not glutamate (Figure 5).

Two-dimensional (2D) ^1H - ^{13}C heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) experiments were performed to confirm these data. JE2 and JE2 *ccpA::ermB* were grown in the presence of $^{13}\text{C}_5$ -glutamate or $^{13}\text{C}_5$ -




Figure 3. Arginine biosynthetic pathway via glutamate and proline. Figure depicts highly conserved arginine biosynthetic pathway via glutamate and the proposed pathway from proline via PutA, RocD, ArcB1, ArgG and ArgH. Note the previously established reverse pathway from arginine to proline via RocF, RocD and ProC. doi:10.1371/journal.ppat.1003033.g003




Figure 5. Determination of arginine biosynthesis-dependent genes in *S. aureus* JE2 *ccpA::tetL*. Defined *bursa aurealis* transposon mutants in *argJ*, *argB*, *argC*, *argF*, *argG*, *argH*, *proC*, *putA*, *rocD*, *arcB1*, and *arcB2* were transduced into JE2 *ccpA::tetL* and assessed for growth in CDM-R for 18 hours. Data represent means \pm SEM of three independent experiments.
doi:10.1371/journal.ppat.1003033.g005

proline in CDM and CDM-R, respectively. Based on our genetic studies, it was predicted that ^{13}C -labeled arginine would only be detected when JE2 *ccpA::ermB* was grown in CDM-R containing $^{13}\text{C}_5$ -proline. As expected, ^{13}C -labeled arginine was detected when JE2 *ccpA::ermB* was propagated in the presence of $^{13}\text{C}_5$ -proline but not with $^{13}\text{C}_5$ -glutamate (Figure 6). Collectively, these results provide strong evidence that proline is the substrate for arginine biosynthesis in a *ccpA* genetic background. Furthermore, it is demonstrated that the highly conserved arginine biosynthetic pathway via glutamate is inactive under the growth conditions utilized in the study.

Arginine Auxotrophy in Other *Staphylococcus aureus* Strains

To determine whether our data regarding arginine biosynthesis were specific to the JE2 background, $\phi 11$ transducing lysates were prepared from JE2 *bursa aurealis* *argF* and *argH* mutants and introduced into RN4220 and Newman *ccpA* backgrounds. As previously noted with JE2 *ccpA::tetL*, an *argH* mutation abolished the ability of both RN4220 *ccpA::tetL* and Newman *ccpA::tetL* to grow in CDM-R, whereas a mutation in *argF* had no effect (Figure 7). Interestingly, RN4220 has the ability to grow in CDM-R broth. Subsequent studies demonstrated that RN4220 reverted to arginine prototrophy at a frequency of 1.6×10^{-5} ; however, sequence analysis of these mutants indicated they did not have mutations in *ccpA*, *hprK* or *ptsH* suggesting weak carbon catabolite repression in the RN4220 strain background. In addition, RN4220 *argH::ΦNΣ* was unable to grow in CDM-R broth whereas a *bursa aurealis* mutation in *argF* had no effect on growth suggesting RN4220 synthesizes arginine from proline but not from glutamate. Collectively, these data suggest that as a species, *S.*




Figure 6. Two-dimensional (2D) ^1H - ^{13}C heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) analysis of JE2 and JE2 *ccpA::ermB*. JE2 and JE2 *ccpA::ermB* were grown in the presence of $^{13}\text{C}_5$ -glutamate or $^{13}\text{C}_5$ -proline in CDM and CDM-R, respectively, and assayed using 2D ^{13}C HSQC NMR. The differences in ^{13}C -arginine relative intensity were determined by subtracting the average intensities between JE2 and JE2 *ccpA::ermB*, and a student's t-test was utilized to determine significance. A positive relative intensity value is indicative of a greater intensity of ^{13}C -arginine in JE2 *ccpA::ermB* in comparison to JE2. JE2 *ccpA::ermB* accumulated significantly greater amounts of ^{13}C -arginine when grown in CDM containing $^{13}\text{C}_5$ -proline in comparison to JE2. Note that there was no significant difference in ^{13}C -arginine accumulation between JE2 and JE2 *ccpA::ermB* when grown in CDM and CDM-R, respectively, containing $^{13}\text{C}_5$ -glutamate.
doi:10.1371/journal.ppat.1003033.g006

aureus has evolved to synthesize arginine via proline when growing in conditions lacking a preferred carbon source.

Virulence in a mouse kidney abscess model. C57BL/6 mice were inoculated retro-orbitally with 10^6 CFU of JE2, JE2 *argH::ΦNΣ*, JE2 *argC::ΦNΣ*, JE2 *putA::ΦNΣ*, or JE2 *argF::ΦNΣ*. The mice were harvested at 20 days and the kidneys were homogenized and CFU/gram of tissue determined (Figure 8). No statistical difference was determined between JE2 and JE2 *argF::ΦNΣ*, JE2 *argC::ΦNΣ*, or JE2 *putA::ΦNΣ*. However, a significant difference was noted between JE2 (mean \log_{10} CFU of 5.31) and JE2 *argH::ΦNΣ* (mean \log_{10} CFU of 4.21) indicating a potential function of *argH* and arginine biosynthesis in abscess development and persistence.

Discussion

The study of arginine biosynthesis has served as a paradigm for the regulon concept, originally coined by Maas and Clark, where the same transcriptional repressor regulates unlinked loci, ArgR [28]. Based on these studies and over 60 years of research, there are three established biochemical pathways, all utilizing glutamate as a substrate, that synthesize arginine in bacteria [27]. These three pathways primarily differ in the enzymes used to generate L-citrulline from N-acetyl-L-ornithine [27,29]. All sequenced staphylococcal species analyzed to date encode the highly conserved ArgJBCDFGH on three separate unlinked transcriptional units; two operons (*argDCJB* and *argGH*) and one monocistronic gene (*argF*). Within the *S. aureus* USA300 FPR_3757 genome




Figure 7. Determination of arginine biosynthesis-dependent genes in *S. aureus* Newman and RN4220. Defined *bursa aurealis* transposon mutants in *argF* and *argH* were transduced into Newman *ccpA::tetL* and RN4220 *ccpA::tetL* and assessed for growth in CDM-R for 18 hours. Data represent means \pm SEM of three independent experiments.
doi:10.1371/journal.ppat.1003033.g007

(NC_007793), the genes predicted to encode the arginine biosynthetic pathway are as follows: *argJ* (bifunctional ornithine acetyltransferase/glutamate N-acetyltransferase), SAUSA300_0185, EC 2.3.1.35/2.3.1.1; *argB* (acetylglutamate kinase), SAUSA300_0184, EC 2.7.2.8; *argC* (N-acetyl-gamma-glutamyl-phosphate-reductase), SAUSA300_0186, EC 1.2.1.38; *argD* (acetylornithine transaminase), SAUSA300_0187, EC 2.6.1.11; *argF* (ornithine carbamoyl transferase), SAUSA300_1062, EC 2.1.3.3; *argG* (argininosuccinate synthase), SAUSA300_0864, EC 6.3.4.5; and *argH* (argininosuccinate lyase), SAUSA300_0863, EC 4.3.2.1. However, as previously reported and confirmed in this study, *S. aureus* is a functional arginine auxotroph when grown on complex laboratory media [8,9]. In addition, no nonsense mutations or insertions were detected within the *argJBCDFGH* genes of the USA300 FPR_3757 genome or any other sequenced staphylococcal genome, suggesting that arginine biosynthesis is not a decaying pathway in the staphylococci. As discussed by Somerville and Proctor, in some cases, amino acid auxotrophies in *S. aureus* may be linked to TCA cycle inactivity or feedback inhibition due to growth in amino acid and glucose replete media [30]. Our results are in agreement with this hypothesis where inactivation of *ccpA*, which represses the TCA cycle [31] and other genes that function to metabolize secondary carbon sources, was linked to arginine biosynthesis in *S. aureus*. In the presence of a preferred carbon source, the CcpA/Hpr complex represses a multitude of genes linked to central metabolism, amino acid metabolism and virulence [2,32,33,34]. Therefore, based on previous studies, bioinformatic analyses of the




Figure 8. Mouse kidney abscess model. C57BL/6 mice were infected with 10^6 CFU of JE2 ($n = 16$ mice), JE2 *argF::ΦNΣ* ($n = 14$ mice), JE2 *argH::ΦNΣ* ($n = 15$ mice), JE2 *argC::ΦNΣ* ($n = 13$ mice), or JE2 *putA::ΦNΣ* ($n = 18$ mice). Kidneys were homogenized after 20 days and bacterial burden determined through viable count (CFU/gram tissue). Horizontal line represents median log₁₀ CFU/gram; significant differences in bacterial burden were noted between JE2 and JE2 *argH::ΦNΣ* (** $p < .01$). Data were analyzed using two-way ANOVA.
doi:10.1371/journal.ppat.1003033.g008

S. aureus genome, and the work by Li and colleagues demonstrating that proline biosynthesis was linked to *ccpA* regulation, it was not unexpected to discover that arginine biosynthesis was linked to carbon catabolite repression [5,18,30,35]. However, it was remarkable to discover that *S. aureus* does not use the conserved *argJBCDFGH* pathway to synthesize arginine via glutamate. Rather, we provide both genetic and biochemical evidence in support of a novel biosynthetic pathway, whereby *S. aureus* utilizes proline as a substrate via the urea cycle. First, mutations within *putA*, *rocD*, *arcB1*, *argG*, and *argH*, but not *argJ*, *argB*, *argC*, or *argF*, abolished growth of a *ccpA* mutant on CDM-R, providing genetic evidence that proline serves as a precursor for arginine synthesis (Figure 5). It is important to note that inactivation of *arcB1* abrogated growth of JE2 *ccpA::tetL* whereas a mutation in *arcB2* did not. *arcB1* (SAUSA300_2569) encodes the native ornithine carbamoyltransferase within the arginine deiminase operon whereas *arcB2* (SAUSA300_0062; ornithine carbamoyltransferase) is within the ACME pathogenicity island encoded arginine deiminase operon [36]. These data suggest that ArcB1 and ArcB2 are not functionally redundant or are not expressed under the same growth conditions. *arcB2* transcript is not detected using northern analysis (data not shown) under *in vitro* growth conditions used in this study (CDM or CDM-R broth), however, it is unknown whether it is induced under other *in vivo* or *in vitro* growth conditions. Second, 2D ^1H - ^{13}C HSQC NMR experiments provided compelling evidence that arginine is synthesized via proline and the urea cycle in a *S. aureus* *ccpA* mutant. Although there have been two reports demonstrating that proline is synthesized from arginine in *S. aureus* [17,18], we are unaware of any reports demonstrating that arginine can be synthesized from proline. Li and colleagues demonstrated that CcpA binds to a *cre* site just upstream of *rocD*. Using the *cre* site from *pckA* as a consensus sequence [18], we identified potential *cre* sites upstream of *putA*, *arcB1*, and *argGH* (Figure S2). However, the function of these *cre* sites in regards to CcpA regulation has yet to be defined.

Previous studies have demonstrated that a *S. aureus* *ccpA* mutant also synthesizes proline from arginine via RocF (arginase), RocD (ornithine aminotransferase), and ProC (P5C reductase) [17,18].

Collectively, these data and our observations suggest that under carbon-limiting conditions (*in vivo* environment), *S. aureus* can synthesize proline from arginine and arginine from proline depending on which amino acid is limited. Based on our findings and the existing literature, we propose a hypothetical model whereby free arginine is limited in the host during infection causing competition between the host and bacteria for arginine. In humans, L-arginine is a non-essential amino acid under homeostatic conditions. However, arginine becomes a “conditionally essential” [37] amino acid during sepsis or trauma due to its use as a substrate for inducible nitric oxide synthase [38] and function in cell-mediated immunity [39], protein synthesis [40] and wound healing [41,42]. Indeed, recent studies have shown significant iNOS and arginase expression during *S. aureus* infection [43] (Figure 9), providing further support that a staphylococcal abscess may be an arginine-depleted environment based on the requirement of arginine for these host enzymes to function. In addition, low levels of L-arginine have been reported in plasma during sepsis [37], causing some investigators to suggest the use of L-arginine as a treatment modality [44]. Furthermore, arginine can serve as a substrate for arginine deiminase and subsequent direct ATP generation in the staphylococci [27].

Although little information is available regarding the concentration of free proline in a staphylococcal abscess, proline is the predominant amino acid found in collagen. Collagen is the most abundant protein in animals and type I collagen is a major constituent of the fibrotic wall surrounding staphylococcal abscesses [45] (Figure 9). Furthermore, *S. aureus* encodes two

proteases, SspB and ScpA, which possess the ability to degrade collagen [46,47,48]. Therefore, our model predicts that *S. aureus* utilizes specific proteases to degrade collagen, resulting in the liberation of free proline or proline-containing peptides that are utilized to synthesize arginine via the urea cycle. Strengthening this argument, earlier work demonstrated that mutants lacking the high affinity proline permease PutP are less virulent in animal models of infection [49,50]. This proposed framework was initially tested using a mouse kidney abscess model previously utilized by Cheng and colleagues [51]. In this model, staphylococcal abscesses within the kidney are contained within a pseudocapsule-like structure; we hypothesized an *argH* and *putA* mutant would be attenuated in abscess persistence in comparison to wild type JE2, JE2 *argC::φNΣ* and JE2 *argF::φNΣ* due to the inability to utilize proline from the pseudocapsule as a substrate for arginine synthesis. Supporting our model, in those kidneys containing staphylococcal abscesses, a significant 1 log₁₀ difference was observed between JE2 and JE2 *argH::φNΣ* demonstrating the importance of arginine biosynthesis via the urea cycle in an *in vivo* infection model. As predicted, based on our *in vitro* data, no significant difference was observed between JE2, JE2 *argC::φNΣ*, and JE2 *argF::φNΣ* in the mouse kidney abscess model. However, in contrast to our predicted results, no significant difference in bacterial persistence was detected between JE2 and JE2 *putA::φNΣ*; PutA converts proline into pyrroline-5-carboxylate (Figure 3). It is known that the addition of either citrulline or ornithine to CDM-R can complement JE2 *ccpA::tetL putA::φNΣ* allowing growth. Therefore, it is possible that generation of citrulline or ornithine by arginine deiminase and ornithine carbamoyltransferase [27], respectively, circumvents and complements the proline requirement and facilitates the synthesis of arginine. In addition, since *argGH* is common to both the glutamate and proline pathways leading to the synthesis of arginine, an alternative interpretation of the data is that both pathways are active *in vivo* and have the ability to complement each other.

Finally, we have demonstrated that other *S. aureus* strains synthesize arginine from proline when CcpA activity is abolished, suggesting conservation of this pathway within the species. However, based on the conserved sequence analysis of the ArgJBCDFGH pathway within sequenced *S. aureus* isolates, we predict that this arginine biosynthetic pathway is active under growth conditions or niches that remain to be identified. Further work is required to dissect the evolving dogma regarding arginine metabolism and the relationship between the host and *S. aureus* in the “war for arginine” during infection.

Materials and Methods

Ethics

The clinical *S. aureus* strains used in this study originated from the University of Nebraska Medical Center. The Institutional Review Board at the University of Nebraska Medical Center is charged with reviewing all research involving human subjects. The clinical *S. aureus* strains utilized in the study were de-identified and analyzed anonymously and were therefore exempt from human research committee approval.

Animal experimentation was performed under a University of Nebraska Medical Center approved Institutional Animal Care and Use Committee (IACUC) Protocol to TK. The University of Nebraska Medical Center is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AALAC). In addition, all animals at the University of Nebraska Medical Center are maintained in accordance with




Figure 9. Mouse subcutaneous abscess model. C57BL/6 flank abscesses caused by subcutaneous injection of 5×10^5 CFU of *S. aureus* JE2. Tissues were processed for immunofluorescence staining for either type I collagen (red), inducible nitric oxide synthase (iNOS, red), or arginase (green). In addition to type I collagen, tissues were processed with the DAPI nuclear stain (blue) to accentuate the abscess core. Representative confocal microscopy images are presented for type I collagen (10× magnification) and iNOS/arginase (20× magnification). doi:10.1371/journal.ppat.1003033.g009

the Animal Welfare Act and the DHHS “Guide for the Care and Use of Laboratory Animals.”

Bacterial Strains and Culture Conditions

For determination of arginine auxotrophy, eighty-two *S. aureus* isolates were obtained from a previous collection testing the prevalence of heterogeneous vancomycin intermediate susceptibility [52]. Other bacterial strains used in the study are shown in Table S1. Defined *bursa aurealis* transposon mutants were acquired from the Nebraska transposon mutant library via the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA; <http://www.narsa.net>). Bacterial strains were grown in either Tryptic Soy Broth (TSB; Becton Dickinson, Franklin Lakes, NJ) or Complete Defined Medium (CDM) as previously described except containing 0.25% glucose [53]. Cultures were grown aerobically (1:10 volume to flask ratio) at 37°C, 250 rpm unless otherwise stated. To train JE2 to grow on media lacking arginine, cultures were grown in CDM-R broth for 6 days, at which point the bacteria were inoculated to CDM-R agar. To study the reversion frequency of JE2, Newman and RN4220, the bacteria were grown for 20 hours in 3 mL of CDM. Cells were pelleted, resuspended in 0.9% NaCl, and diluted onto CDM, CDM-R, or CDM-P. After 72 hours the colonies were counted and reversion frequency was determined by taking the number of prototrophic revertants divided by total number of colonies plated on CDM.

To determine the growth characteristics in CDM-R containing various alternative carbon sources, JE2 was grown in 3 mL of CDM overnight, pelleted and resuspended in 0.9% NaCl. 3 mL of CDM and CDM-R supplemented with either 0.25% of glucose, fructose, glycerol, sucrose, mannitol, maltose, salicin, gluconic acid, arabinose, sorbitol, or ribose (all purchased from Sigma-Aldrich, St. Louis, MO) were inoculated in a 14 mL polypropylene round-bottom tube (Becton Dickinson) to an OD₆₀₀ of 0.05. Cultures were grown for 18 h at 37°C to stationary phase.

Screening of Random *bursa aurealis* Transposon Mutant Library

Random *bursa aurealis* transposon mutants were generated using plasmids pBursa and pFA545 and identified using inverse PCR as previously described [54]. Mutants were grown and collected in a 96 well format and pelleted and resuspended in 50 µL of 0.9% NaCl. 2 µL were plated on CDM and CDM-R and incubated at 37°C for 72 hours. Approximately 2700 mutants were screened; colonies that grew on CDM-R plates were confirmed by growing in CDM-R broth.

Transduction, *ccpA* Mutant Construction and Complementation

bursa aurealis transposon mutations were moved to other strain backgrounds through transduction using phage 80α or φ11 as previously described [55]. All primers (Table S2) used for construction and confirmation of the *ccpA* mutation were generated based on the sequence of *S. aureus* strain Mu50 (NC_002758.2). The *ccpA* mutant was constructed by replacing a 0.6 kb internal region of the *ccpA* gene with an erythromycin resistance cassette (*ermB*) using the gene splicing by overlap extension (gene SOEing) technique [56]. *ermB* was amplified from pEC4 [57] using primers SAV1736-*ermB*-f and SAV1736-*ermB*-r, which contain sequences homologous to the *ccpA* gene. Primers BamHI-SAV1737-f and *ermB*-SAV1736-r were used for amplification of a 1.3 kb region upstream of the *ccpA* gene. Primers *ermB*-SAV1736-f and SacI-*acuC*-f were used to amplify a 1.7 kb region downstream of the *ccpA* gene. The resulting 4.1-kb PCR product contained BamHI and SacI sites that

were used for cloning into pTS1-d [58] to generate plasmid pMRS44. Plasmid pMRS44 was used to construct *S. aureus* SA564 *ccpA::ermB* using the temperature shift protocol as previously described [59]. Allelic replacement of the internal region of the *ccpA* gene by the *ermB* cassette was verified by PCR using primers *ermB*-f, *ermB*-r, SAV1737-f and *acuC*-f. The *ccpA::ermB* mutation was subsequently moved to JE2 through phage 80α transduction and confirmed using primers noted above. For the *ccpA* complementation plasmid pNF266, *ccpA* was amplified from JE2 using primers 2250 and 2251 (Table S2), digested with SphI and BamHI, and cloned into pCN51 [60]. Note that two *ccpA* mutants were constructed in this study, JE2 *ccpA::ermB* and JE2 *ccpA::tetL*. JE2 *ccpA::tetL* was generated by phage 80α transduction of the *ccpA::tetL* allele from MST14 [2] so double mutants could be constructed using *ermB* as the second selectable marker.

NMR Data Collection

JE2 and JE2 *ccpA::ermB* were grown in 50 mL CDM to stationary phase. JE2 and JE2 *ccpA::ermB* were subsequently inoculated to an OD₆₀₀ of 0.05 in CDM containing 100 µM of either ¹³C₅-glutamate or ¹³C₅-proline (Isotec) and grown to stationary phase. Cultures were normalized to an OD₆₀₀ of 2.0 and pelleted by centrifugation (3000 rpm, 20 minutes, 4°C). Pellets were subsequently washed in 10 mL of cold sterile water and resuspended in 1 mL cold sterile water. The Pellet was lysed using a bead beater (MP Biomedicals) and centrifuged for 15 minutes at 13,000 rpm at 4°C. This lysis step was repeated two more times and the pellet frozen in an ethanol/dry ice bath. The samples were then lyophilized, suspended in 600 µL of 50 mM phosphate buffer (pH = 7.2, uncorrected) in 99.8% D₂O (Isotec), and transferred to 5 mm NMR tubes for analysis. The NMR spectra were collected on a Bruker 500 MHz Avance spectrometer equipped with a triple-resonance, Z-axis gradient probe. A BACS-120 sample changer with Bruker Icon software was used to automate the NMR data collection. The 2D ¹H-¹³C HSQC spectra were collected with a standard Bruker pulse sequence (HSQCETGP), solvent presaturation and a relaxation delay of 1.5s. Each 2D ¹H-¹³C HSQC spectrum was collected with a spectrum width of 4734.85 Hz and 2048 data points in the direct (¹H) dimension; and a spectrum width of 13834.26 Hz and 64 data points in the indirect (¹³C) dimension. A total of 16 dummy scans and 128 scans were used to obtain each 2D ¹H-¹³C HSQC spectra.

The spectra were processed using the NMRPipe software package [61]. The spectra were Fourier transformed, manually phased, and baseline corrected. The processed 2D ¹H-¹³C HSQC spectra were then analyzed using NMRView [62] to assign chemical shifts and intensities to each peak. The chemical shift list were assigned to specific metabolites using the Human Metabolome Database [63], Madison Metabolomics Database [64], and Platform for Riken Metabolomics [65] with a tolerance level of 0.05 ppm and 0.40 ppm in the ¹H and ¹³C chemical shifts respectively. The presence of metabolites and metabolomics pathways was verified using the Kyoto Encyclopedia of Genes and Genomes (KEGG) [66] and MetaCyc [67] databases. The quantification of metabolomic peak intensities were performed in a similar manner as previously described [68]. The relative percent concentration difference was determined by subtracting averages from the two cultures. A student T-test was performed to verify the significance at a 95% confidence level, of the relative percent concentration differences.

RNA Isolation and Northern Blot Analysis

Cultures of *S. aureus* JE2 and JE2 *ccpA::ermB* were grown overnight in CDM, diluted to an OD₆₀₀ of 0.05 into fresh CDM or

CDM-R (1:10 volume to flask ratio, 250 rpm), and grown at 37°C to an OD₆₀₀ of 1.5 (mid-exponential growth). Cells were pelleted at 3000×g for 20 minutes at 4°C and resuspended in RLT buffer with 1% β-mercaptoethanol. Next, they were transferred to lysing matrix B tubes (MP Biomedicals) and processed in a FP120 FastPrep cell disrupter (MP Biomedicals) for 24 seconds at a setting of 6.0. The cells were pelleted at 13000 rpm at 4°C for 15 minutes; top-phase was combined with 500 μL of ethanol. The samples were then processed using an RNeasy mini kit, according to manufactures instructions (Qiagen, Inc.). Primers listed in Table S2 were used to make DNA probes that were subsequently labeled with digoxigenin-labeled dUTP (Roche). 5 μg of RNA was used for northern analysis that was performed using DIG buffers and washes (Roche). Anti-Digoxigenin-AP Fab fragments (Roche) was used with ECF substrate (GE Healthcare) for detection. Blots were visualized using the Typhoon FLA 7000 imaging system (GE Healthcare).

Amino Acid Analysis

JE2 and JE2 *ccpA::ermB* were grown overnight in 50 mL (500 mL flask) of CDM. Cultures were inoculated to a starting OD₆₀₀ of 0.05 in CDM (100 mL in 1 L flask, 250 rpm, 37°C) and grown for 5 hours. 500 μL of media was collected and pelleted for 5 minutes at maximum speed. Supernatant was collected and filtered through 3,000 MWCO Amicon Ultra centrifugal filters (Millipore) according to manufactures instructions. Amino acid analysis was performed by the Protein Structure Core Facility, UNMC, using a Hitachi L-8800.

Animal Models

Mouse subcutaneous abscess model. Subcutaneous abscesses were established in C57BL/6 mice following the injection of 5×10^5 cfu of *S. aureus* JE2. Tissues were collected at day 7 post-infection and processed for immunofluorescence staining for either type I collagen (Millipore, Billerica, MA), inducible nitric oxide synthase (Abcam, Cambridge, MA), or arginase (Santa Cruz, San Diego, CA). For type I collagen, tissues were incubated with the nuclear stain DAPI to accentuate the abscess core. *Mouse kidney abscess model.* C57BL/6 mice were anesthetized using ketamine and xylazine and 100 μL containing 10^7 CFU of *S. aureus* JE2, JE2 *argH::φNΣ*, or JE2 *argF::φNΣ* were inoculated retro-orbitally. On day 20 following inoculation, the animals were sacrificed and the

kidneys were excised, homogenized, and subsequently plated for bacteriological analysis (CFU/g of tissue) on Trypticase soy agar (TSA). Only those kidneys containing greater than 100 CFU/g of tissue were statistically analyzed. Pairwise comparisons were conducted and differences were adjusted for multiple comparisons using the Tukey-Kramer method to maintain an overall alpha = .05 across all comparisons.

Supporting Information

Figure S1 Amino acid analysis of JE2 and JE2 *ccpA::ermB* following growth in CDM. JE2 and JE2 *ccpA::ermB* were grown in CDM for 18 hours and supernatant was collected and analyzed for amino acid content. Percent of proline and arginine remaining is shown suggesting more efficient utilization of proline by JE2 *ccpA::ermB* in comparison to JE2.

(TIF)

Figure S2 Putative *cre* sites in arginine biosynthesis-dependent genes. Using the *cre* site from *pckA* as a consensus sequence, putative *cre* sites were identified in *rocD*, *arcB1*, *putA*, and *argGH*. *cre* site from *pckA* is the top sequence whereas the putative *cre* site from the identified gene is the bottom sequence.

(TIF)

Table S1 Bacterial Strains and Plasmids used in study. (DOCX)

Table S2 Oligonucleotides used in study. (DOCX)

Acknowledgments

We thank Jennifer Endres, Todd Widhelm, and Vijaya Yajjala for their work on the Nebraska Transposon Library and Amy Aldrich for performing immunofluorescence staining. We also think Lynette Smith and Fang Yu for help with the statistical analysis.

Author Contributions

Conceived and designed the experiments: ASN RP PDF. Performed the experiments: ASN SMH. Analyzed the data: ASN SMH RP PDF. Contributed reagents/materials/analysis tools: MRS MLH KWB TK. Wrote the paper: ASN SMH RP PDF.

References

- Deleo FR, Otto M, Kreiswirth BN, & Chambers HF (2010) Community-associated methicillin-resistant *Staphylococcus aureus*. *Lancet* 375: 1557–1568.
- Seidl K, Stucki M, Ruegg M, Goerke C, Wolz C, et al. (2006) *Staphylococcus aureus* CcpA affects virulence determinant production and antibiotic resistance. *Antimicrob Agents Chemother* 50: 1183–1194.
- Majerczyk CD, Sadykov MR, Luong TT, Lee C, Somerville GA, et al. (2008) *Staphylococcus aureus* CodY negatively regulates virulence gene expression. *J Bacteriol* 190: 2257–2265.
- Pohl K, Francois P, Stenz L, Schlink F, Geiger T, et al. (2009) CodY in *Staphylococcus aureus*: a regulatory link between metabolism and virulence gene expression. *J Bacteriol* 191: 2953–2963.
- Somerville GA, Proctor RA (2009) At the crossroads of bacterial metabolism and virulence factor synthesis in *Staphylococci*. *Microbiol Mol Biol Rev* 73: 233–248.
- Zhu Y, Nandakumar R, Sadykov MR, Madayiputhiya N, Luong TT, et al. (2011) RpiR Homologues May Link *Staphylococcus aureus* RNAIII Synthesis and Pentose Phosphate Pathway Regulation. *J Bacteriol* 193: 6187–6196.
- Zhu Y, Weiss EC, Otto M, Fey PD, Smeltzer MS, et al. (2009) Tricarboxylic acid cycle-dependent attenuation of *Staphylococcus aureus* in vivo virulence by selective inhibition of amino acid transport. *Infect Immun* 77: 4256–4264.
- Emmett M, Kloos WE (1975) Amino acid requirements of staphylococci isolated from human skin. *Can J Microbiol* 21: 729–733.
- Gladstone GP (1937) The nutrition of *Staphylococcus aureus*; nitrogen requirements. *Br J Exp Pathol* 18: 322–333.
- Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa, et al. (2001) Whole genome sequencing of methicillin-resistant *Staphylococcus aureus*. *Lancet* 357: 1225–1240.
- Cunin R, Glansdorff N, Pierard A, Stalon V (1986) Biosynthesis and metabolism of arginine in bacteria. *Microbiological reviews* 50: 314–352.
- Vogel RH, Vogel HJ (1963) Acetylated intermediates of arginine synthesis in *Bacillus subtilis*. *Biochim Biophys Acta* 69: 174–176.
- Prozesky OW (1967) Arginine synthesis in *Proteus mirabilis*. *J Gen Microbiol* 49: 325–334.
- Rodriguez-Garcia A, de la Fuente A, Perez-Redondo R, Martin JF, Liras P (2000) Characterization and expression of the arginine biosynthesis gene cluster of *Streptomyces clavuligerus*. *J Mol Microbiol Biotechnol* 2: 543–550.
- Leisinger T (1987) Proline Biosynthesis. In: Neidhardt F, Ingraham JL, Low K, Magasanik B, Schaechter M, & Umberger H, editors. *Escherichia coli* and *Salmonella typhimurium*: Cellular and Molecular Biology. Washington DC: ASM Press. pp. 345–357.
- Abdelal AT (1979) Arginine catabolism by microorganisms. *Annu Rev Microbiol* 33: 139–168.
- Townsend DE, Kaenjak A, Jayaswal RK, Wilkinson BJ (1996) Proline is biosynthesized from arginine in *Staphylococcus aureus*. *Microbiology* 142: 1491–1497.
- Li C, Sun F, Cho H, Yelavarthi V, Sohn C, et al. (2010) CcpA mediates proline auxotrophy and is required for *Staphylococcus aureus* pathogenesis. *J Bacteriol* 192: 3883–3892.
- Stulke J, Hillen W (1999) Carbon catabolite repression in bacteria. *Curr Opin Microbiol* 2: 195–201.
- Deutscher J, Kuster E, Bergstedt U, Charrier V, Hillen W (1995) Protein kinase-dependent HPr/CcpA interaction links glycolytic activity to carbon catabolite repression in gram-positive bacteria. *Mol Microbiol* 15:1049–1053.

21. Henkin TM (1996) The role of CcpA transcriptional regulator in carbon metabolism in *Bacillus subtilis*. FEMS Microbiol Lett 135:9–15.
22. Hueck CJ, Hillen W (1995) Catabolite repression in *Bacillus subtilis*: a global regulatory mechanism for the gram-positive bacteria? Mol Microbiol 15: 395–401.
23. Schumacher MA, Allen GS, Diel M, Seidel G, Hillen W, et al. (2004) Structural basis for allosteric control of the transcription regulator CcpA by the phosphoprotein HPr-Ser46-P. Cell 118: 731–741.
24. Deutscher J, Saier MH, Jr. (1983) ATP-dependent protein kinase-catalyzed phosphorylation of a seryl residue in HPr, a phosphate carrier protein of the phosphotransferase system in *Streptococcus pyogenes*. Proc Natl Acad Sci U S A 80: 6790–6794.
25. Mijakovic I, Poncet S, Galinier A, Monedero V, Fioulaine S, et al. (2002) Pyrophosphate-producing protein dephosphorylation by HPr kinase/phosphorylase: a relic of early life? Proc Natl Acad Sci U S A 99: 13442–13447.
26. Sonenshein AL (2007) Control of key metabolic intersections in *Bacillus subtilis*. Nat Rev Microbiol 5: 917–927.
27. Lu CD (2006) Pathways and regulation of bacterial arginine metabolism and perspectives for obtaining arginine overproducing strains. Appl Microbiol Biotechnol 70: 261–272.
28. Maas WK (1964) Studies on the Mechanism of Repression of Arginine Biosynthesis in *Escherichia coli*. II. Dominance of Repressibility in Diploids. J Mol Biol 8: 365–370.
29. Xu Y, Labedan B, Glansdorff N (2007) Surprising arginine biosynthesis: a reappraisal of the enzymology and evolution of the pathway in microorganisms. Microbiol Mol Biol Rev 71: 36–47.
30. Somerville GA, Proctor RA (2009) The Biology of Staphylococci. In: Crossley KB, Jefferson KK, Archer GL, & Fowler VG, editors. Staphylococci in Human Disease. Oxford: Blackwell Publishing Ltd. pp. 3–18.
31. Sadykov MR, Hartmann T, Mattes TA, Hiatt M, Jann NJ, et al. (2011) CcpA coordinates central metabolism and biofilm formation in *Staphylococcus epidermidis*. Microbiology 157: 3458–3468.
32. Seidl K, Bischoff M, Berger-Bachi B (2008) CcpA mediates the catabolite repression of *tst* in *Staphylococcus aureus*. Infect Immun 76: 5093–5099.
33. Seidl K, Goerke C, Wolz C, Mack D, Berger-Bachi B, et al. (2008) *Staphylococcus aureus* CcpA affects biofilm formation. Infect Immun 76: 2044–2050.
34. Seidl K, Muller S, Francois P, Kriebitzsch C, Schrenzel J, et al. (2009) Effect of a glucose impulse on the CcpA regulon in *Staphylococcus aureus*. BMC Microbiol 9: 95.
35. Becker SA, Palsson BO (2005) Genome-scale reconstruction of the metabolic network in *Staphylococcus aureus* N315: an initial draft to the two-dimensional annotation. BMC Microbiol 5: 8.
36. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, et al. (2008) The arginine catabolic mobile element and staphylococcal chromosomal cassette *mec* linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant *Staphylococcus aureus*. J Infect Dis 197: 1523–1530.
37. Davis JS, Anstey NM (2011) Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis. Crit Care Med 39: 380–385.
38. Fang FC (1997) Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 99: 2818–2825.
39. Ochoa JB, Strange J, Kearney P, Gellin G, Endean E, et al. (2001) Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr 25: 23–29.
40. Luiking YC, Poeze M, Ramsay G, Deutz NE (2005) The role of arginine in infection and sepsis. JPEN J Parenter Enteral Nutr 29: S70–74.
41. Shi HP, Most D, Efron DT, Witte MB, Barbul A (2003) Supplemental L-arginine enhances wound healing in diabetic rats. Wound Repair Regen 11: 198–203.
42. Witte MB & Barbul A (2003) Arginine physiology and its implication for wound healing. Wound Repair Regen 11: 419–423.
43. Thurlow LR, Hanke ML, Fritz T, Angle A, Aldrich A, et al. (2011) *Staphylococcus aureus* biofilms prevent macrophage phagocytosis and attenuate inflammation in vivo. J Immunol 186: 6585–6596.
44. Kalil AC (2011) Is it time to replace L-arginine in severe sepsis? Crit Care Med 39: 417–418.
45. Shoulders MD, Raines RT (2009) Collagen structure and stability. Annu Rev Biochem 78: 929–958.
46. Kantyka T, Shaw LN, Potempa J (2011) Papain-like proteases of *Staphylococcus aureus*. Adv Exp Med Biol 712: 1–14.
47. Ohbayashi T, Irie A, Murakami Y, Nowak M, Potempa J, et al. (2011) Degradation of fibrinogen and collagen by staphopains, cysteine proteases released from *Staphylococcus aureus*. Microbiology 157: 786–792.
48. Rice K, Peralta R, Bast D, de Azavedo J, McGavin MJ (2001) Description of staphylococcus serine protease (*ssp*) operon in *Staphylococcus aureus* and nonpolar inactivation of *sspA*-encoded serine protease. Infect Immun 69: 159–169.
49. Bayer AS, Coulter SN, Stover CK, Schwan WR (1999) Impact of the high-affinity proline permease gene (*putP*) on the virulence of *Staphylococcus aureus* in experimental endocarditis. Infect Immun 67: 740–744.
50. Coulter SN, Schwan WR, Ng EY, Langhorne MH, Ritchie HD, et al. (1998) *Staphylococcus aureus* genetic loci impacting growth and survival in multiple infection environments. Mol Microbiol 30(2): 393–404.
51. Cheng AG, Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, et al. (2009) Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. FASEB J 23: 3393–3404.
52. Pitz AM, Yu F, Hermesen ED, Rupp ME, Fey PD et al. (2010) Vancomycin Susceptibility Trends and Prevalence of Heterogeneous Vancomycin-Intermediate *Staphylococcus aureus* (hVISA) in Clinical Methicillin-Resistant *S. aureus* (MRSA) Isolates. J Clin Microbiol 49: 269–274.
53. Hussain M, Hastings JG, White PJ (1991) A chemically defined medium for slime production by coagulase-negative staphylococci. J Med Microbiol 34: 143–147.
54. Bae T, Banger AK, Wallace A, Glass EM, Aslund F, et al. (2004) *Staphylococcus aureus* virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc Natl Acad Sci U S A 101: 12312–12317.
55. Climo MW, Sharma VK, Archer GL (1996) Identification and characterization of the origin of conjugative transfer (*oriT*) and a gene (*nes*) encoding a single-stranded endonuclease on the staphylococcal plasmid pGO1. J Bacteriol 178: 4975–4983.
56. Horton RM, Cai ZL, Ho SN, Pease LR (1990) Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques 8: 528–535.
57. Bruckner R (1997) Gene replacement in *Staphylococcus carnosus* and *Staphylococcus xylosus*. FEMS Microbiol Lett 151: 1–8.
58. Sadykov MR, Olson ME, Halouska S, Zhu Y, Fey PD, et al. (2008) Tricarboxylic acid cycle-dependent regulation of *Staphylococcus epidermidis* polysaccharide intercellular adhesin synthesis. J Bacteriol 190: 7621–7632.
59. Foster TJ (1998) Molecular Genetic Analysis of Staphylococcal Virulence. In: Williams P, Ketley J, & Salmond GPC, editors. Methods in Microbiology, Bacterial Pathogenesis. San Diego: Academic Press. pp. 433–454.
60. Charpentier E, Anton AI, Barry P, Alfonso B, Fang Y, et al. (2004) Novel cassette-based shuttle vector system for gram-positive bacteria. Appl Environ Microbiol 70: 6076–6085.
61. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, et al. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6: 277–293.
62. Johnson BA (2004) Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods in molecular biology 278: 313–352.
63. Wishart DS, Knox C, Guo AC, Eisner R, Young N, et al. (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37: D603–610.
64. Cui Q, Lewis IA, Hegeman AD, Anderson ME, Li J, et al. (2008) Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol 26(2): 162–164.
65. Akiyama K, Chikayama E, Yuasa H, Shimada Y, Tohge T, et al. (2008) PRIME: a Web site that assembles tools for metabolomics and transcriptomics. In Silico Biol 8: 339–345.
66. Okuda S, Yamada T, Hamajima M, Itoh M, Katayama T, et al. (2008) KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res 36: W423–426.
67. Caspi R, Altman T, Dale JM, Dreher K, Fulcher CA, et al. (2010) The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res 38: D473–479.
68. Zhang B, Halouska S, Schiafo CE, Sadykov MR, Somerville GA, et al. (2011) NMR analysis of a stress response metabolic signaling network. J prot Res 10: 3743–3754.